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ABSTRACT 
Repair of skeletal muscle after sarcolemmal damage involves dysferlin and dysferlin-interacting 
proteins such as annexins. Mice and patient lacking dysferlin exhibit chronic muscle 
inflammation and adipogenic replacement of the myofibers. Here we show that similar to 
dysferlin, lack of annexin A2 (AnxA2) also results in poor myofiber repair and progressive 
muscle weakening with age. By longitudinal analysis of AnxA2-deficient muscle we find that 
poor myofiber repair due to the lack of AnxA2 does not result in chronic inflammation or 
adipogenic replacement of the myofibers. Further, deletion of AnxA2 in dysferlin deficient mice 
reduced muscle inflammation, adipogenic replacement of myofibers, and improved muscle 
function. These results identify multiple roles of AnxA2 in muscle repair, which includes 
facilitating myofiber repair, chronic muscle inflammation and adipogenic replacement of 
dysferlinopathic muscle. It also identifies inhibition of AnxA2-mediated inflammation as a novel 
therapeutic avenue for treating muscle loss in dysferlinopathy. 
  
INTRODUCTION 
Skeletal muscle responds to minor damage of the myofiber sarcolemma by repair of the damaged 
membrane. However, myofibers that fail to repair and undergo necrotic death, are replaced 
through regeneration. Together, repair and regeneration of the injured myofibers enable repair of 
muscle injury. While myofiber repair involves subcellular processes that occur over minutes 
following injury, myofiber regeneration involves inflammatory and myogenic processes that 
occur over hours to days following injury (1,2). Cellular proteins that coordinate myofiber repair 
and regeneration over this timescale to ensure efficient muscle repair, are poorly understood. 
Proteins that can coordinate both, myofiber repair and myofiber regeneration in vivo should be 
able to 1) sense and respond to myofiber injury, 2) activate inflammatory and myogenic cells in 
response to myofiber injury, and 3) facilitate myogenesis to replace necrotic myofibers. Defects 
in the above processes exacerbate tissue damage and lead to the loss of muscle function, 
underscoring the need to identify proteins and the mechanisms involved in it.  
Annexins are calcium binding proteins that regulate various intracellular events that are 
altered in muscle diseases (3-7). Recent in vitro and in vivo studies of myofibers and other cells 
have found that annexin and their binding partners are recruited to and facilitate repair of plasma 
membrane (PM) injury (8-13). A role of annexins in myofiber regeneration is supported by our 
previous analysis of Annexin A1 and by gene expression analysis of muscles acutely injured in 
vivo by cardiotoxin injection, which shows expression of annexins, including annexins A1 and 
A2 increases immediately following injury and remains elevated for days, during the course of 
muscle repair (Fig. S1;(14), (15)). In addition to myofiber regeneration, in vivo and ex vivo 
analyses show that annexins also mediate tissue inflammation (15-18). Tissue inflammation has 
a complex relationship with muscle repair, while acute inflammation is required for myofiber 
regeneration chronic inflammation causes muscle disease (1). Such muscle diseases include 
Limb Girdle Muscular Dystrophy (LGMD) 2B and Miyoshi Myopathy (MM), which are caused 
by mutations in dysferlin gene. Lack of dysferlin compromises repair of myofibers following ex 
vivo sarcolemmal injury, and leads to chronic inflammation, increased muscle degeneration and, 
gradual adipogenic replacement of myofibers in vivo (19-25). Eccentric exercise accelerates 
disease progression and adipogenic muscle replacement in dysferlinopathic mice and patients 
(26,27). However, with the link between the incidence of in vivo sarcolemmal lesions and 
dysferlinopathic myofiber degeneration due to myofiber loss and adipogenic replacement being 
unclear, the basis for dysferlinopathic muscle pathology remains elusive. 
Dysferlinopathic muscles show increased macrophages, in addition to CD4+ and CD8+ 
cells (28,29). While muscle inflammation is required during early phase of muscle repair (30), 
the basis for increased and chronic inflammation in dysferlinopathy remains enigmatic. Some of 
the suggested links for poor muscle repair and inflammation in dysferlinopathy include the 
chemotactic factor thrombospondin 1 (31), TNF-α (32), and complement factor C3 (33). Testing 
the importance of these links is complicated by discordant effects of reducing muscle 
inflammation in dysferlinopathy: while use of anti-inflammatory steroid therapy is not beneficial 
for dysferlinopathy, loss of B and T lymphocytes and loss of Toll-like receptor (TLR)-mediated 
innate immune response reduces muscle pathology and improves muscle strength (34-36). Thus, 
to develop anti-inflammatory therapy for LGMD2B there is a need to identify the link between 
poor myofiber sarcolemmal repair and chronic muscle inflammation. Annexins have been 
postulated as a regulator of disease in dysferlinopathy as annexins, such as annexin A1 and A2 
co-localize and interact with dysferlin in injured muscle cells (13,37). Annexins A1 and A2 are 
also increased in LGMD2B patients and mice, in a manner that correlates positively with the 
severity of their symptoms (6,37,38).  
Using AnxA1-null mice we recently identified that AnxA1 deficit does not compromise 
repair of injured myofibers but slows satellite cell fusion and thus myofiber regeneration (15). 
Here, we have examined the role of AnxA2 in repair of injured muscles. We have tested the role 
of AnxA2 in healthy and dysferlin-deficient mouse (B6A/J) muscle using mice lacking AnxA2 
(A2) or lacking AnxA2 and dysferlin (B6A/JA2). Similar to dysferlin deficient myofibers, 
AnxA2-deficient myofibers poorly repair injury to their sarcolemma and show a progressive age-
dependent decline in muscle function. However, unlike the dysferlin-deficient muscle, AnxA2-
deficient muscles do not exhibit chronic inflammation even as muscle function declines with age. 
While AnxA2-deficient dysferlinopathic myofibers repair poorly, these muscles exhibit reduced 
inflammation. This identifies a need for AnxA2 to activate chronic inflammation caused by poor 
repair. In the absence of AnxA2, dysferlinopathic muscle shows extensive myofiber 
regeneration, but not degeneration or adipogenic replacement. These reductions in muscle 
histopathology occur concomitantly with improved muscle strength and in vivo muscle function. 
Thus we identify AnxA2 as a regulator of myofiber repair and muscle inflammation, which 
facilitates adipogenic conversion of dysferlinopathic muscle and is thus a potential target to treat 
dysferlinopathy.  
RESULTS 
Annexin A2 is required for myofiber sarcolemmal repair  
With the association of annexin A2 to dysferlin and the role of annexin A2 in PM repair in non-
muscle cells (9,37), we examined the PM repair ability of Anx2-deficient (A2) myofibers. To 
monitor the kinetics of repair, myofibers in intact isolated muscles were injured ex vivo by focal 
laser injury as we previously described (21,39,40). The kinetics of sarcolemmal repair following 
injury was monitored by measuring the cellular entry of membrane impermeable dye FM1-43. 
Injury to parental wild type (WT; C57BL/6) and A2 mice showed that lack of AnxA2 reduced 
the ability of the injured myofibers to repair (Fig. 1A, B). Next, we examined the effect of 
AnxA2 deficit on repair of myofibers injured mechanically by ex vivo lengthening contraction 
(LC)-induced injury. Using Extensor Digitorum Longus (EDL) and Soleus (SOL) muscles we 
monitored the recovery of muscle contractile force and the ability to exclude entry of cell 
impermeant dye procion orange following repeated LC injury by stretching of 10% for fast 
(EDL) and slow (SOL) muscle. Both EDL and SOL muscles from A2 mice showed a greater 
decrease in contractile force following each round of LC injury (Fig. 1C, D). After 9 consecutive 
LC injuries, A2 EDL muscle showed over 20% greater loss in contractile force as compared to 
the WT muscle (Fig. 1C). To assess the extent of sarcolemmal injury due to LC-injury, injured 
EDL muscle was incubated in cell impermeant dye procion orange. Compared to WT EDL 
muscle, more myofibers in the A2 muscle were labeled with procion orange (Fig. 1E). Thus, use 
of two independent assays to monitor the repair of injured myofibers shows that, similar to what 
is known for dysferlin, lack of AnxA2 also reduces the ability of injured myofibers to repair. 
Mice lacking Annexin A2 show age-dependent loss of muscle function 
Due to the reduced ability of the A2 myofiber to repair sarcolemmal injury, we next assessed the 
effect of AnxA2 deficit on in vivo muscle growth and function. Over the first 9 months of life A2 
mice showed similar increase in body and muscle mass as the parental WT, but by 12 months the 
increase in body mass and muscle mass declined in the A2 animals, but the myofibers did not 
show concomitant decrease in size, indicating they were not atrophic (Fig. S2A-F). To assess the 
effect of AnxA2 deletion on muscle strength we performed in vivo and ex vivo measurements of 
muscle contractile strength. In vivo measurement of the forelimb grip strength showed a decrease 
in grip strength of A2 mice at 3 months of age and the forelimb continued to remain weaker at all 
ages tested till 12 months old (Fig. 2A). To assess if there is a potential involvement of 
neurological effects in the decrease of in vivo contractile force, we measured the contractile 
ability of isolated EDL muscle ex vivo. EDL muscle from A2 mice showed a lower force 
production starting from 3 months of age, but the difference became significant starting from 6 
months old and continued to remain weak even thereafter (Fig. 2B). These results indicate that 
lack of AnxA2 decreases muscle force generation. To assess if the decline in muscle strength is 
reflected in voluntary physical activity of the A2 animals we measured activity of the mice in an 
open field behavioral assessment at 3 and 6 months of age. At 3 months of age, the activity of A2 
mice was indistinguishable from the WT mice, but by 6 months of age, A2 mice showed a 2 to 5-
fold decline in all the activity measures assessed (Fig. 2C-E). Together, these data show that 
AnxA2 deficit recapitulates the age dependent decrease in muscle strength and physical activity 
seen in dysferlinopathy. 
Lack of Annexin A2 does not cause muscle inflammation and degeneration 
In view of the above similarities in the effect of dysferlin and AnxA2 deficit at the cellular and 
tissue level, we next examined if AnxA2 and dysferlin deficient muscle also exhibit similar 
changes in gene expression. Principal component analysis of the microarray gene expression data 
for the Gastrocnemius (GSC) muscles of 6 months old AnxA2 deficient and parental WT mice (n 
= 4 per group) showed no clustering of samples into the two genotypes (Fig. S3A). Accordingly, 
we observed only 6 differentially-expressed genes (including AnxA2) with a false discovery rate 
(FDR) of < 0.1 (Table S1). To test for accumulation of weak changes across gene sets we carried 
out gene set enrichment analysis against 2,510 canonical pathways, gene ontology terms, and 
gene lists derived from previous muscle gene expression studies. This identified 16 gene sets 
with FDR < 0.1, many of which are related to protein degradation (Fig. S3B). Leading edge 
analysis suggested this is driven by the up-regulation of a small subset of proteasomal subunit 
proteins (Fig. S3B, C). This is a modest change in gene expression as compared to the hundreds 
of genes that show altered expression in recent studies of dysferlin deficient muscles (41-43). 
Dysferlin deficient muscles show a notable increase in muscle inflammation (44). For a focused 
analysis of alterations in inflammatory genes between AnxA2 and dysferlin deficient mouse 
muscles we compared muscle gene expression data obtained from the A2 muscle with complete 
transcriptomic profiles of 3 recent murine dysferlinopathic muscle studies GSE2629 (41), 
GSE2507 (42), and GSE2112 (43). None of the inflammation-related gene ontology (GO) terms 
dysregulated in these dysferlin-deficient datasets were dysregulated in the A2 muscle (Table S2).  
To further examine this lack of any remarkable change in inflammatory gene expression 
in the 6 months old A2 muscle, we performed longitudinal muscle histopathological analysis of 
the GSC muscle from A2, WT and dysferlinopathic (B6A/J) mice at 3, 6 and 9 months of age 
(Fig. 3A). In agreement with the gene expression analysis we observed that compared to the 
dysferlinopathic (B6A/J) muscle, A2 muscles showed relatively little histopathology even at 9 
months of age. While compared to the WT muscle, B6A/J GSC muscle showed an increase in 
the number of degenerating fibers, inflammatory foci and regenerating fibers at all ages (up to 
17, 20 and 35-fold respectively at 9 months), A2 muscle do not show any difference (Fig. 3B-D). 
Thus, despite similar loss in ex vivo measures of myofiber repair and muscle function for AnxA2 
and dysferlin deficient mice, AnxA2 deficient mice exhibit minimal muscle histopathology and 
inflammation in vivo. 
Annexin A2 links poor myofiber repair and dysferlinopathic muscle inflammation 
AnxA2 facilitates inflammatory signaling, and increase in AnxA2 expression in dysferlinopathic 
and regenerating muscle is linked with increased muscle inflammation (6,17,38,45). We thus 
hypothesized that the lack of A2 muscle inflammation despite poor myofiber repair indicates a 
requirement of AnxA2 for triggering muscle inflammation. To test this hypothesis we generated 
mice deficient in dysferlin and AnxA2. As the A2 mice are on the C57BL/6 strain, we cross-bred 
it with dysferlin deficient mice on the C57BL/6 strain - B6A/J (27). Genotype of the 
dysferlin/AnxA2 null (B6A/JA2) mice was confirmed as before (21,46) (Fig. S4A, B). The 
B6A/JA2 mice were viable, with no obvious defect in growth and development (Fig. 4A-C).  
To test the ability of myofibers from the B6A/JA2 mice to repair sarcolemmal injury we 
used the ex vivo laser injury assay as described above. PM injury in the B6A/JA2 myofibers 
resulted in even greater FM dye entry as compared to the B6A/J myofibers, indicating their 
reduced ability to repair sarcolemmal injury (Fig. 4D). Further, this indicates that AnxA2 helps 
with repair of the dysferlinopathic myofibers. If the role of AnxA2 in muscle injury was limited 
to its role in myofiber repair, this observation would predict a worse pathology for B6A/JA2 
mice as compared to the B6A/J mice. However, if as per our hypothesis, AnxA2 does indeed link 
myofiber repair deficit with muscle inflammation, B6A/JA2 mice will have reduced 
inflammation and thus reduced muscle pathology as compared to B6A/J mice. Since muscle 
pathology in B6A/J mouse gets progressively worse at older ages, we examined histology of 
muscle sections in old (> 18 months) WT, A2, B6A/J and B6A/JA2 mice (Fig. 4E). As 
previously shown in GSC (Fig 3) there was significantly greater number of degenerating and 
regenerating fibers, as well as inflammatory foci in the EDL muscle of B6A/J mice as compared 
to the WT and A2 mice (Fig. 4F-H). However, in comparison to B6A/J muscles, EDL muscles of 
18-24 months old B6A/JA2 showed 2 to 7-fold decreases in the number of degenerating fibers, 
regenerating fibers, and inflammatory foci (Fig. 4F-H). This reduction in muscle pathology was 
also observed in all the other muscles, namely Tibialis Anterior (TA), GSC, and Psoas that were 
examined (Fig. S5). This identifies that AnxA2 deficit is protective against the muscle 
degeneration caused by dysferlin deficit. 
As an independent assessment of the nature of muscle inflammation, we quantified 
inflammatory markers for B cell, T cell, macrophages, and TLR-mediated innate immune 
response, all of which are involved in dysferlinopathy (35,36,47). Using qRT-PCR we assessed 
expression of B cell marker CD19, T cell markers CD4, CD8A, macrophage marker EMR1 
(F4/80), and innate immune signaling (TLR4, IL12, and TNFα). Compared to 18-24 months old 
WT muscles, these markers were unaltered in age-matched A2 muscles, but up-regulated in age-
matched B6A/J muscle (Fig. 4I, J). Compared to B6A/J muscle, B6A/JA2 muscles showed up to 
7-fold reduction in expression of B and T lymphocyte markers, and showed a trend for reduced 
expression of TLR4 as well as TLR-regulated genes IL-12 and TNFα (Fig. 4I, J). However, the 
expression of the macrophage marker F4/80 (EMR1) was unaltered (Fig. 4I). These results show 
that lack AnxA2 inhibits inflammation of dysferlin deficient muscles even at late symptomatic 
stage. 
Adipogenic conversion of the dysferlinopathic muscle depends on Annexin A2  
Previous studies have shown that dysferlin deficiency in patients and animals results in a 
significant fatty replacement of muscles cells in age and symptom dependent manner, which may 
relate to altered inflammatory response due to dysferlin deficit (23,24). To assess appearance of 
adipogenic signature in muscle we used the transcriptomic profiles of GSC muscle from 
dysferlinopathic mice (GSE2629 (41), GSE2507 (42), and GSE2112 (43)) for GO terms relating 
to cellular markers for adipogenic and fatty acid metabolism genes to assess if any of these were 
dysregulated in muscle of 7 months old dysferlin deficient mice (Table S2). To aid in 
interpretation of this analysis, we also assessed these GO terms in a dataset comparing adipose 
tissue to muscle (GSE51866). Adipogenic GO terms dysregulated in 7 months old dysferlin 
deficient muscle changed similarly to that observed for the fat versus muscle comparison; 
however, similar to the young (< 2 months old) dysferlin deficient muscles, these terms were not 
dysregulated in AnxA2 deficient muscles. This identifies that adipogenic GO terms that are 
responsive to disease progression in dysferlin deficient muscle are unaltered in AnxA2 deficient 
muscle. In agreement with the results from gene expression analysis, histological analysis of 
one-year old GSC muscle showed obvious signs of adipogenic muscle replacement in 
dysferlinopathic muscle, while WT and AnxA2 muscle were showed no detectable adipogenic 
conversion (Fig. 5A). Use of Oil red O staining showed that adipogenic deposits are found 
within and between myofibers, both of which are missing from age matched GSC muscle from 
WT and AnxA2 deficient mice. Interestingly, these adipogenic deposits are significantly reduced 
in B6A/JA2 mice (Fig. 5B). To quantify the extent of adipogenic conversion of muscle we 
immunostained the muscles with lipid droplet specific protein Perilipin1 which is not abundant 
in healthy muscle (48). Unlike WT muscles, Perilipin1 staining was abundant in B6A/J muscle, 
but lacking in A2 as well as B6A/JA2 muscles (Fig. 5C, D). While the staining was observed 
both within the myofiber (arrows) and between the myofibers (arrowheads), the little Perilipin1 
staining observed in B6A/JA2 muscle rarely occurred within the myofiber.  
To assess if the lack of adipogenic replacement of B6A/JA2 muscle is due to a delay (not 
a block) in adipogenic conversion of muscle we further investigated multiple muscles by H&E 
and Oil Red O staining (Fig. S4C, S5). These staining showed that there is a gradation of 
adipogenic replacement of dysferlinopathic muscle with Psoas, and GSC muscles being more 
affected than EDL and TA (Fig. 4E, S4C). Similar to the EDL muscles from two-year old B6A/J 
mice, which showed reduced histopathology in AnxA2 and in B6A/JA2 muscle (Fig. 4E), we 
observed consistently reduced lipid deposition in all B6A/JA2 muscles when compared to B6A/J 
(Fig. S5). In view of the poor myofiber repair of B6A/J and B6A/JA2 muscles, but protection of 
B6A/JA2 muscle from adipogenic replacement, this demonstrates the requirement of AnxA2 to 
trigger adipogenic conversion of dysferlin deficient myofibers. 
Lack of Annexin A2 improves dysferlinopathic muscle function 
Due to the reduced inflammation and adipogenic conversion of muscle we hypothesized that 
AnxA2 deficiency may improve dysferlinopathic muscle function. We first tested if AnxA2 and 
dysferlin deficient muscle show improved muscle strength in vivo. To assess muscle contractile 
ability we measured the forelimb and hindlimb grip strength at pre-symptomatic (< 6 months 
old) and late symptomatic (> 20 months old) B6A/J and B6A/JA2 mice. B6A/JA2 showed a 
significantly slower decline in grip strength of both the limbs as the disease progressed. While 
the grip strength of both limbs was similar between pre-symptomatic B6A/J and B6A/JA2 mice, 
B6A/JA2 mice showed significantly greater grip strength than B6A/J muscle at the late 
symptomatic age (Fig. 6A, B). As the decline in muscle strength in late symptomatic B6A/JA2 
mice occurs despite poor myofiber sarcolemmal repair (Fig. 4D), we assessed if this is due to an 
improved ability of the asymptomatic and early symptomatic B6A/JA2 muscles to withstand 
injury. To test this we subjected 6 and 12 months old EDL muscle from B6A/J and B6A/JA2 
mice to ex vivo eccentric injury by repeated 10% LC. At both these ages we observed that the 
EDL muscles from B6A/JA2 mice were more resistant to damaging effects of LC injury, 
resulting in reduced loss in contractile force upon successive LC injuries (Fig. 6C). The 
improved resistance of B6A/JA2 EDL muscles to LC injuries is not due to an increase in the 
strength of the EDL muscle as shown by similar maximal EDL contractile force of B6A/J and 
B6A/JA2 at pre-symptomatic, as well as early and late symptomatic ages (Fig. 6D). 
With the improved function and reduced adipogenic conversion of the B6A/JA2 muscle, 
we tested if this reflects in the functional measures of activity of the mice. For this we performed 
open-field measurements of activities of mice at early-symptomatic (≤ 6 months) and late-
symptomatic (> 20 months) age. As compared to B6A/J mice, B6A/JA2 mice displayed 
significantly increased activity in all the measures tested, including total vertical and horizontal 
activities, as well as total number of all voluntary movements (Fig. 6 E-G), as a level similar or 
close to WT animals. All the measures of voluntary activities were noticeably improved at both 
stages, such that B6A/JA2 mice showed increased movement by 50% at early age and 20% at 
late age (Fig. 6F) and vertical activity was improved by as much as 3-fold in early-symptomatic 
stage and increased to 6-fold by late-symptomatic stage (Fig. 6E). Taken together, analysis of 
muscle function and voluntary activities demonstrate that the reduced muscle pathology in the 
B6A/JA2 mice results in improved functional performance of these mice offering a strong 
indication in support of functional benefits of AnxA2 deficiency in dysferlinopathic muscle. 
DISCUSSION 
Muscular dystrophies such as LGDM2B and Miyoshi Myopathy are characterized by poor 
myofiber repair, exhibit chronic muscle inflammation and degeneration (19,22,23,25,46). 
Dysferlin, the protein mutated in LGMD2B and MM, interacts with AnxA1, and AnxA2, and is 
required for sarcolemmal repair (37). Studies in C. elegans have underlined the importance of 
dysferlin interaction with annexins in sarcolemmal repair (13). Annexin A6 has been the only 
annexin implicated so far in sarcolemmal repair in mammals (4). Mutation of AnxA6 was 
recently identified to worsen muscle repair and pathology in a dysferlinopathic mouse model 
(49). Our recent analysis of AnxA1 deficient mice identified that instead of facilitating 
sarcolemmal repair, AnxA1 facilitates myoblast fusion required for the regeneration of injured 
myofibers (15). Similar to the role of AnxA1 in non-muscle cells, we have found that AnxA2 is 
required for repairing injury to the plasma membrane (9,12). Here we show that AnxA2 is also 
required for the repairing injured mouse myofibers. Our studies with AnxA2 identified that 
AnxA2 helps with plasma membrane repair by facilitating F-actin buildup at the site of injury 
(9). F-actin buildup has also been shown to facilitate repair of injured myofibers (8,50). In light 
of the ability of AnxA2 to interact with F-actin and with dysferlin, it is plausible that AnxA2 
facilitates sarcolemmal repair by facilitating F-Actin buildup and dysferlin recruitment at the 
injured plasma membrane (50). However, with the role of AnxA2 in aggregating and fusing 
membranes, AnxA2 may also facilitate fusion of dysferlin containing membranes at the site of 
cell membrane injury (3,50). 
Similar to dysferlin, lack of AnxA2 also causes poor myofiber repair and progressive 
decline in muscle function. However, AnxA2 deficiency does not cause inflammation, or lead to 
degeneration of the muscles, identifying AnxA2 as the protein that regulates myofiber repair as 
well as injury-triggered muscle inflammation. Dysferlinopathic patient muscles show adipogenic 
replacement of myofibers and increasing disease severity with increasing level AnxA2 in the 
muscle (6,23,26). Such a role of AnxA2 is further supported by previous reports showing that 
AnxA2 expression is increased rapidly following injury of healthy muscle, and during the course 
of disease progression in dysferlinopathic patients (6,14,37,38). These two distinct roles of 
AnxA2 may be linked to the two distinct localizations of AnxA2 – intracellular (for membrane 
repair) and extracellular (for activating inflammation). Despite lacking a signal peptide, AnxA2 
is secreted by cells in a variety of tissues where AnxA2 binds cell surface receptors (51). 
Extracellular AnxA2 activates inflammation by regulating shedding of pro-tumor necrosis factor-
alpha and by functioning as a ligand of TLR4 (17,45,52). Activation of classical innate immune 
response due to poor repair of dysferlinopathic myofiber has been shown to play a role in disease 
progression (33). Additionally, poor cell membrane repair is also proposed to activate alternate 
innate immune signaling through the release of Danger Associated Molecular Patterns (DAMPs) 
(53). One such DAMP is the high mobility group 1 (HMGB1) protein which, similar to AnxA2, 
resides in the cell and upon secretion activates inflammation (54). A role of HMGB1 as a DAMP 
has been proposed for dystrophin deficient muscle, but protein(s) responsible for activating 
innate immune response in dysferlinopathy has not been identified. This role of AnxA2 is 
supported by the reduced expression of TLR-regulated genes in AnxA2 deficient muscle.  
In addition to muscle inflammation, a recently identified feature of dysferlinopathic 
patient and mouse muscle is adipogenic replacement of myofibers (23). Adipogenic replacement 
of muscle is a feature of symptomatic patient muscles, which is exacerbated by eccentric 
exercise-induced muscle injury (23,26). Adipogenic replacement of muscle correlates with the 
onset of muscle weakness and enhancing disease severity enhances fatty deposition in 
dysferlinopathic muscles (24,55). Thus, a viable therapeutic approach to treat dysferlinopathy is 
one which can minimize muscle adipogenic conversion. It was suggested that adipogenic 
pathology in dysferlin-deficient muscle is regulated by transcription factor CCAAT/enhancer 
binding protein-δ. By deletion of AnxA2 in dysferlinopathic muscle here we have identified 
AnxA2 is necessary for adipogenic conversion of dysferlin deficient myofibers. It is worth 
noting that AnxA2 knockout reduces inflammation and adipogenic conversion of dysferlin 
deficient muscle despite poor myofiber repair ability. Deletion of AnxA2 in dysferlin deficient 
mice (B6A/JA2 mice) lowers the level of TLR4 and other inflammatory mediators (Fig. 4). 
Recently, importance of TLR signaling for dysferlinopathic muscle pathology was uncovered by 
the knockout of Myd88 - the central facilitator of TLR signaling, which reduced histopathology 
and improved dysferlinopathic muscle function (36). By identifying that loss of AnxA2 improves 
dysferlinopathic muscle function, here we show AnxA2 functions as a link between poor 
myofiber repair and ensuing inflammation and adipogenesis in dysferlinopathic muscle. It 
appears to do so by linking muscle injury and TLR4-mediated chronic muscle inflammation with 
subsequent adipogenic replacement of dysferlinopathic myofibers (Fig. S6). Future studies using 
inflammatory and non-inflammatory cell-specific AnxA2 knockout will help determine the 
relative contribution of muscle and inflammatory cells in adipogenic replacement of dysferlin-
deficient muscle and the nature of the signal that leads to myofiber adipogenesis. The 
observation that AnxA2 deficit breaks the link between poor myofiber repair and 
dysferlinopathic muscle pathology provides direct evidence that approaches to prevent 
adipogenic conversion of dysferlinopathic muscle can be therapeutic even when myofiber repair 
is deficient. Additionally, in view of the link between muscle adipogenic conversion and clinical 
severity in dysferlinopathy it identifies blocking AnxA2 function as a potential therapy for 
dysferlinopathy. Insight into the mechanism by which AnxA2 links dysferlin deficit to 
dysferlinopathic muscle degeneration will help unravel the mechanism by which muscle injury, 
inflammation and adipogenesis are coordinated in dysferlinopathy and provide additional 
avenues for developing therapies for dysferlinopathy.  
 
MATERIALS AND METHODS 
Animal: Methods involving animals were approved by the local institutional animal research 
Committee and animals were maintained in a facility accredited by the American Association for 
Accreditation of Laboratory Animal Care. Wild type (WT) mice (C57BL/6) were obtained from 
Jackson Laboratory (Bar Harbor, ME), annexin A2 knockout mice (A2) were a gift of Dr. 
Katherine Hajjar from Cornell University Medical Center (New York) and dysferlin deficient 
mice (B6A/J) were a gift of Dr. I Richard from Genethon (Paris). To generate mice lacking both 
dysferlin and annexin A2 (B6A/JA2), B6A/J mice were crossed with A2 mice. Homozygous null 
mice for annexin A2 and dysferlin were obtained in F2 generation and genotyped as described 
below. 
PCR genotyping: To assess the status of both dysferlin null allele and annexin A2 null allele, 
genomic DNA was PCR amplified as described before by (21) for dysferlin allele and (46) for 
annexin A2 allele (Fig. S4). The primers used to identify dysferlin mutation (A/J Etn insertion in 
intron 4) were: dysf-F, 5’-TTCCTCTCTTGTCGGTCTAG-3’; dysf-R, 5’-
CTTCACTGGGAAGTATGTCG-3’; ETn-oR, 5’-GCCTTGATCAGAGTAACTGTC-3’ and for 
annexin A2 allele: A2WT, 5’-GCACAGCAATTCATCACACTAATGTCTTCTTG-3’; A2KO, 
5’-GCTGACTCTAGAGGATCCCC-3’; Anint, 5’-TGCGCCACCACGCCCGGCTT 
GTGCTTGCCAC-3’. 
Ex vivo cell membrane injury: Extensor Digitorum Longus (EDL) or Soleus (SOL) muscle 
were surgically isolated from euthanized WT, A2, B6A/J and B6A/JA2 mice in Tyrode’s 
solution and laser injury was carried out as described (39) in the Tyrode’s buffer containing 1.33 
mg/ml FM1-43 dye. The kinetics of repair was determined by measuring the cellular FM1-43 
dye fluorescence. FM-dye intensity (F-F0 where F0 is the original value) was used to quantify the 
kinetics of cell membrane repair and represented with intervals of 5 frames. 
Ex vivo force contraction: Mice at the age of 3, 6, 9, 12 and/or 24 months were anesthetized 
with intraperitoneal injections containing ketamine (100 mg/kg) and xylazine (10 mg/kg).  From 
the right hindlimb, EDL muscle was dissected and brought into a bath containing Ringer solution 
(composition in mM: 137 NaCl, 24 NaHCO3, 11 glucose, 5 KCl, 2 CaCl2, 1 MgSO4, 1 NaH2PO4, 
and 0.025 turbocurarine chloride) at 25ºC that was bubbled with a mixture of 95%O2 and 
5%CO2.  With 6-0 silk suture, the proximal tendon was tied to a fixed bottom plate and the distal 
tendon was tied to the arm of a force transducer (Aurora Scientific, Ontario, Canada, model 
305B). The muscle was surrounded by two platinum electrodes to stimulate the muscle. The 
optimal length of the muscle was established using single 0.2 ms square stimulation pulses. At 
optimal length, with tetani 300 ms in duration and at frequencies of 30, 100, 150, 200, 220 and 
250 Hz, each separated by 2 min intervals, the maximal force of the EDL was measured and 
normalized for the muscle cross section area. After measuring the length of the muscle with 
calipers, the muscle was removed from the bath and weighed. The cross section was calculated 
based on muscle mass, fiber length and muscle tissue density.  Fiber length was determined 
based on the ratio of fiber length to muscle length of 0.45 (56). The same procedure was repeated 
for SOL muscle from the right hind limb, but the stimulation duration was 1000 ms at 
frequencies of 30, 50, 80 and 100 Hz. The fiber length to muscle length for the SOL muscle was 
0.71. Before removing the EDL or SOL muscle from the bath, the muscle was subjected to a 
protocol of lengthening contractions. At optimal length, the EDL muscle was stimulated at 250 
Hz for 300 ms until a plateau of maximal force generation was reached. From this plateau, with 
the muscle stimulated, the muscle was lengthened over 10% of its length with a velocity of 2 
fiber lengths per second after which the muscle was passively returned to the optimal length. 
This was repeated 9 times with 1 min interval between the lengthening contractions. The same 
procedure was repeated for the SOL muscle, but the muscle was stimulated for 1000 ms at 100 
Hz and the muscle was lengthened over 10% its length. After removal of the SOL muscle, the 
mice were euthanized by CO2 asphyxiation.   
Procion orange staining: After performing the ex vivo lengthening contraction injury muscles 
were placed in 0.2% procion orange dye solution (in Ringer’s) for 1 hour at room temperature. 
After removing the excess dye by washing with Ringer’s solution, the muscle was immediately 
frozen using isopentane pre-chilled in liquid nitrogen. Frozen tissues were sectioned (8 µm) and 
imaged under red channel using a Nikon Eclipse E800 (Nikon, Japan) microscope that was fitted 
with a SPOT digital color camera with SPOT advanced software (Diagnostic Instruments, 
Sterling Heights, MI). Representative pictures (20X) were taken and procion orange positive 
fibers/image were measured for each section.  
Grip strength measurement: At 3, 6, 9, 12 and > 20 months, forelimb and hindlimb grip 
strength were performed in the morning hours with Grip Strength Meter (GSM, Columbus 
instruments, Columbus, USA) as described (57). The absolute GSM values (Kgf) for each 
measurement were used for analysis. The grip strength measurements were collected over a 5-
day period after a period of acclimation of 5 days. 
Open-field behavioral activity measurements (Digiscan): At 3, 6 and > 20 months, voluntary 
locomotor activity (movement number, horizontal activity and vertical activity) was measured 
using an open field digiscan apparatus (Omnitech Electronics, Columbus, Ohio, USA) as 
described previously (57). Locomotor activity data were collected over a 1-hour period in the 
morning hours over a 4 consecutive days with a previous period of acclimation of 4 days. 
Expression profiling: Directly following euthanasia, Gastrocnemius (GSC) muscles from the 
left hindlimb were directly frozen liquid nitrogen and stored at -80˚C. Total RNA was extracted 
from frozen GSC muscles using Trizol reagent (Life Technologies, USA) and cleaned up with 
RNeasy MinElute cleanup kit (Qiagen, USA) according to the manufacturers’ instructions, and 
then stored at -80oC until use. RNA samples were analyzed with GeneChip Mouse Genome 430 
2.0 microarrays (Affymetrix, Santa Clara, CA). An aliquot of 250 ng of total high-quality RNA 
from each sample was used. cDNA and biotinylated cRNA were synthesized using the 
Affymetrix GeneChip®  3’ IVT Express Target Amplification, Labeling and Control Reagent kit 
according to manufacturer’s instructions. 15.2 ug of biotinylated cRNA was fragmented and 
hybridized to Affymetrix Gene-Chips MG 430 2.0 for 16 hours. The arrays were washed and 
stained on the Affymetrix Fluidics station 400 and scanned with a Hewlett Packard G2500A 
gene Array Scanner according to manufacturer’s protocol.  
Bioinformatics functional analyses: For datasets for which raw chip image files were available 
(A2, GSE2507, GSE51866), the following analysis pipeline was followed: (1) microarray quality 
control was carried out by checking the % present, average background, scale factors and 
GAPDH and actin 3’::5’ ratios for each chip using the affyQCReport R package from 
Bioconductor (58), and by NUSE and RLE analysis as described previously (59); (2) robust 
multichip averaging (RMA), consisting of background adjustment, quantile normalization and 
probeset summarization (60); (3) the characteristic direction geometrical approach was then used 
to identify differentially expressed genes (DEGs) (61). For dataset GSE2629, raw chip image 
files were unavailable, so characteristic direction analysis was run on the expression matrix 
provided by that study’s authors, after log2 transformation. For dataset GSE2112, only a 
published list of differentially expressed genes with fold-changes and p-values was available. For 
calculation of FDR q-values for the A2 dataset (since characteristic direction does not give a 
measure of significance), a separate differential expression analysis was carried out using NIA 
Array Analysis (62). For the A2 dataset, principal component analysis (PCA) was carried out 
using TM4: Multi-experiment Viewer (63). Rank-based gene set enrichment tests were done 
using GSEA (64) on normalized, non-log2, gene expression values, applying default settings 
(e.g. permutations on phenotype, collapse genes to max of probesets) except that minimum 
overlap with gene sets was changed from 15 to 8 to allow for the small sizes of some dysferlin-
related muscle gene sets. Gene Sets were taken from the Muscle Gene Sets homepage (Muscle 
Gene Sets v1) http://sys-myo.rhcloud.com/muscle_gene_sets.php and from MSigDB 
http://software.broadinstitute.org/gsea/msigdb/. Gene set enrichment mapping was generated 
using Cytoscape (65) and Enrichment Map (66). Enrichment tests for inflammation-related and 
fat-related gene ontology terms were carried out on the most differentially expressed 250 genes 
from each comparison, using Enrichr (67). The gene expression data are publicly available from 
the Gene Expression Omnibus (GEO), series number GSE87557. 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87557  
Histopathology scoring: Directly following euthanasia, GSC or EDL muscles from the left 
hindlimb were removed and embedded in OCT and snap frozen in liquid nitrogen-cooled 
isopentane. For histological analysis, muscles embedded in OCT were subsequently sectioned 
and stained with haematoxylin and eosin (H&E) as far as possible using the TREAT-NMD 
guidelines for the DMD mouse (http://www.treat-nmd.eu/research/preclinical/dmd-sops/). The 
slides were acquired at 40X magnification with Nanozomer microscope (Hamamatsu, Japan) or 
with VS120 (Olympus, USA) with OlyVIA software, and myofibers in muscle section were 
assessed for the following features: central nuclei/muscle, regenerating (centrally nucleated) 
fibers/muscle, and degenerating and necrotic myofibres (that show microscopic evidence of 
structural damage to the myofibers such as hypercontraction and fragmented sarcoplasm that is 
accompanied with or without the inflammatory cell invasion) using Image J (NIH). 
Quantitative RT-PCR: Directly following euthanasia, GSC muscles from the left hindlimb 
were directly frozen liquid nitrogen and stored at -80˚C. To isolate RNA for qRTPCR analysis, 
frozen GSC muscles were homogenized in Trizol (Life technologies) with homogenizer 
according to manufacturer’s instructions. After RNA isolation, RNA was quantified on a 
Nanodrop N1000 spectrophotometer and a total of 300 ng of RNA was used to produce cDNA 
using ABI High Capacity cDNA Kit (Thermofisher). Taqman mouse primers were used: CD19, 
CD4, CD8A, EMR1, IL12, TLR4, TNFα and HRPT (Thermofisher). All qRTPCR reactions 
were prepared according to manufacturer’s instructions using ABI Taqman Gene Expression 
Master Mix (Thermofisher) and measured on ABI 7900HT Fast-Time PCR System through SDS 
2.4 software. Relative gene expression was calculated using the ∆Ct method, with HRPT as the 
internal reference gene with RQ Manager 1.2.1 software. 
Lipid staining: To monitor the presence of lipids, Oil red O staining was performed with 8 µm 
frozen sections from the GSC of 12 months old WT, A2, B6A/J and B6A/JA2 (n = 3 animals per 
group) using a commercial staining kit (American MasterTech, Lodi CA, USA), as per 
manufacturer instructions. To quantify skeletal muscle lipid deposition, frozen 8 µm GSC 
sections were fixed with chilled 4% paraformaldehyde and incubated with anti-perilipin A/B 
(Sigma Aldrich; Cat #: P1873) at 5 µg/mL in PBS-Tween with 1% BSA and 10 % goat serum. 
Perilipin staining was visualized using goat ant-rabbit conjugated to A568 (4 µg/mL, 
ThermoFisher) and co-stained with A488-conjugated wheat germ agglutinin (2 µg/mL, 
ThermoFisher) to mark sarcolemmal membranes. Sections were mounted with ProLong Gold 
including DAPI and imaged using a VS120 slide scanner (Olympus). Perilipin images were 
thresholded in MetaMorph, and the number and average size of perilipin-positive foci in the 
entire section was quantified using the program’s Integrated Morphometry Analysis.  
Statistics: Unless otherwise stated, all analyses were performed using GraphPad Prism version 
5. Normality test was assessed for each measurement. Value which was < or > average ± 2 
standard deviation was removed. Data are presented as means ± S.E.M. or as medians ± extreme 
values through whisker plot. Statistical analyses were performed using Student’s t-test, ANOVA 
or Kruskal Wallis test for each age-matched data. Nominal statistical signifance was set at p ≤ 
0.05. 
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FIGURES 
Figure 1:  Lack of AnxA2 causes poor sarcolemmal repair. (A) Freshly isolated intact Soleus 
(SOL) muscle isolated from WT or A2 mice were injured ex vivo in presence of FM1-43 dye. 
The images show time lapse images of fibers visualized for brightfield (pre injury, left panel), 
and for fluorescence emission of the FM dye pre and post injury (middle, right panels). 
Individual myofibers are marked by dotted white line, and arrows indicated the site of 
sarcolemmal injury. Scale bar = 20 µm. (B) Quantification of FM1-43 influx, following laser 
injury, into fiber isolated from WT in presence (n = 14 fibers) or absence of calcium (n = 4 
fibers) and AnxA2 deficient (n = 22 fibers) mice. (C) Percentage of initial force as a result of 
repeated 10% ex vivo lengthening contractions of WT or A2 Extensor Digitorum Longus (EDL) 
muscle from 1 year old animal (n = 3-4 animals each). (D) Percentage of initial force as a result 
of repeated 10% ex vivo lengthening contractions of WT or A2 SOL muscle from 1 year old 
animal (n = 3 animals each). (E) Cross-section of EDL muscle section stained with procion 
orange following 10 repeated lengthening contractions in WT and A2 from 1 year old animal: 
brightfield (left panel) and procion orange (right panel). Scale bar = 50 µm. All images were 
acquired and scaled similarly and quantifications show means ± S.E.M. B: ** p ≤ 0.01 and *** p 
≤ 0.001 compared to WT and ### p ≤ 0.001 compared to A2 by ANOVA ; C : * p ≤ 0.05 
compared to WT by unpaired t-test.  
Figure 2: AnxA2 deficient mice show progressive muscle weakness and decline in 
locomotor activity. A2 and parental WT mice at different ages (3 to 24 months old) were 
assessed for muscle strength and voluntary locomotor activity. (A) Forelimb grip strength 
measurement (GSM). (B) Specific force of isolated Extensor Digitorum Longus (EDL) muscle. 
(C - E) Voluntary locomotor activity assessed by open-field behavior measurements. All data are 
expressed as medians ± extreme values through whisker plot (n > 9 animals). * p ≤ 0.05, ** p ≤ 
0.01 and *** p ≤ 0.001 compared to WT by unpaired t-test. 
Figure 3: Annexin A2 deficit does not increase muscle degeneration and inflammation. 
Gastrocnemius (GSC) muscle sections from A2, WT and dysferlin deficient (B6A/J) mice at 
different ages (3, 6 and 9 months old) were stained with haematoxylin & eosin (H&E) and 
various histological features were quantified. (A) Representative histological images of GSC 
muscle for WT, A2 and B6A/J mice. (B) H&E stained muscle sections were imaged from >4 
independent animals and the entire muscle section was used to quantify the number of (B) 
degenerated fibers (open arrow), (C) inflammatory foci (white arrow) and (D) centrally 
nucleated fibers (black arrow). Scale bar = 100 µm. All data are expressed as mean ± S.E.M (n > 
4 animals). * p ≤ 0.05 and** p ≤ 0.01 compared to WT and # p ≤ 0.05 compared to A2 by 
Kruskal Wallis test. 
 
Figure 4: Lack of AnxA2 reduces muscle inflammation in dysferlinopathic mouse. B6A/J 
and B6A/JA2 mice at 6-24 months of age were assessed for (A) body mass and (B, C) muscle 
mass (Gastrocnemius, GSC or Tibialis Anterior, TA), as well as (D) the ability of the myofiber 
from Extensor Digitorum Longus (EDL) or biceps muscle of B6A/J (n = 13 fibers) or B6A/JA2 
(n = 15 fibers) mice to repair from laser injury ex vivo. (E) Representative histological images of 
the haematoxylin & eosin stained EDL muscle cross section from WT, A2, B6A/J and B6A/JA2 
at 24 months old. Scale bar = 100 µm.  Number of (F) degenerating muscle fibers (open arrow), 
(G) inflammatory foci (white arrow) and (H) central nucleated fibers (black arrow) were 
quantified from entire EDL muscles of WT, A2, B6A/J and B6A/JA2 at 24 months of age (n > 3 
animals). (I, J) mRNA expression level (normalized to HPRT and presented as fold-change over 
the WT) for (I) various inflammatory cell population and (J) genes involved in TLR-signaling 
response in A2, B6A/J or B6A/JA2 GSC muscle at 24 months (n > 3 animals). All data are 
expressed as means ± S.E.M. $$ p ≤ 0.01 compared to B6A/J by unpaired t-test. * p ≤ 0.05 and 
** p ≤ 0.01 compared to WT and ## p ≤ 0.01 compared to A2 by Kruskal Wallis test.  
Figure 5: Lack of AnxA2 reduces fatty replacement of dysferlinopathic muscles. 
Gastrocnemius muscle from 12 month old WT, A2, B6A/J and B6A/JA2 mice were stained with 
(A) haematoxylin & eosin, (B) Oil Red O and (C) immunostained for Perilipin1 (red). Scale = 
200 µm for A & B and 100 µm for C. (D) Using images of whole muscle section the number of 
perlilipin1 stained foci were quantified (n = 3 animals each). Blue: DAPI, Green: Wheat germ 
Agglutinin (Alexa Fluor 488 conjugate), and Red: Perilipin1 (Alexa fluor 568 conjugate).The 
plots represent mean ± SEM. * p ≤ 0.05 compared to WT by Kruskal Wallis test. 
Figure 6: Lack of AnxA2 improves dysferlinopathic muscle function. (A, B). Forelimb and 
hindlimb grip strength (GSM) measurement of B6A/J or B6A/JA2 mice at < 6 months and WT, 
B6A/J or B6A/JA2 at > 20 months (n > 10 animals). (C) Percentage of initial force as a result of 
successive 10% ex vivo lengthening contractions of B6A/J or B6A/JA2 Extensor Digitorum 
Longus (EDL) muscle from 6 months or 1 year old animal (n > 4 animals). (D) Specific force of 
EDL muscle from B6A/J or B6A/JA2 mice at 6, 12 and 24 months (n > 6 animals). (E-G) 
Voluntary locomotor activity assessed by open-field behavioral activity measurements of B6A/J 
or B6A/JA2 mice at < 6 months and WT, B6A/J or B6A/JA2 mice at > 20 months (n > 10 
animals). Box whisker plots show median ± extreme values, while line plot (C) shows means ± 
S.E.M. A, B, E-G : * p ≤ 0.05 and *** p ≤ 0.001 compared to WT and $ p ≤ 0.05, $$ p ≤ 0.01 
and $$$ ≤ 0.001 compared to B6A/J by Kruskal Wallis test ; C :  * p ≤ 0.05, ** p ≤ 0.01 and *** 
p ≤ 0.001 compared to B6A/J by ANOVA. 
  
Table S1: Microarray probe sets showing differential expression (FDR q-value < 0.1) in A2 
muscles as compared to age matched parental WT muscle. 
Symbol Fold-Change P-value FDR 
AnxA2 -2.67 0 0 
Nedd4 5.75 0 0.00273 
Ppcdc -1.87 0 0.00273 
2210418O10Rik -1.61 0.00001 0.04454 
Tpm1 2.06 0.00001 0.04454 
Dynlt1a|Dynlt1b|Dynlt1c|Dynlt1f 1.85 0.00001 0.04836 
 
  
Table S2: Enrichment of inflammation-related and fat-related gene ontology terms among the 
250 most differentially expressed genes (as compared against their respective wild-type controls) 
in muscle of the 6 months old A2 murine model and from datasets of dysferlin-deficient murine 
muscles at 7 months (GSE2507), 2 months (GSE2112), or 1 month (GSE2629_QF, 
GSE2629_TA) of age; P-values of 0.1 or less are shown, while the rest were considered not 
significant (NS). *For fat-related gene ontology terms, an additional dataset (GSE51866) for fat 
tissue vs muscle tissue was included for comparison. 
 
A2  
Dysferlin-deficient Fat versus 
muscle 
(GSE51866)* 
 
GSE2507 GSE2112 GSE2629_QF GSE2629_TA 
Inflammation-related Gene Ontology terms 
Inflammatory response NS NS 0.002 0.002 0.001 
 
Regulation of inflammatory 
response 
NS 0.003 0.001 0.009 0.007  
Positive regulation of 
inflammatory response 
NS 0.009 0.016 0.087 0.003  
Activation of innate immune 
response 
NS 0.002 NS NS 0.003  
Activation of immune 
response 
NS 0.010 NS NS NS  
Adaptive immune response NS 0.002 0.075 0.094 NS  
Positive regulation of innate 
immune response 
NS 0.006 NS NS 0.012  
Adipose-related Gene Ontology terms 
Brown fat cell differentiation NS 0.079 NS NS 0.017 < 0.001 
Fatty acid metabolic process NS 0.019 NS NS NS 0.016 
Fatty acid oxidation NS 0.003 NS NS NS 0.060 
ABBREVIATIONS 
Annexin (Anx), danger associated molecular patterns (DAMP), differentially expressed genes 
(DEG), Extensor Digitorum Longus (EDL), false discovery rate (FDR), gene expression omnibus 
(GEO), gene oncology (GO), Gastrocnemius (GSC), grip strength meter (GSM), haematoxylin 
and eosin (H&E), high mobility group (HMG), lengthening contraction (LC), Limb Girdle 
Muscular Dystrophy (LGMD), Miyoshi Myopathy (MM), principal component analysis (PCA), 
plasma membrane (PM), Psoas (PSO), Soleus (SOL), Tibialis Anterior (TA), toll-like receptor 
(TLR) and wild type (WT).  
  
 
 
Figure 1:  Lack of AnxA2 causes poor sarcolemmal repair. (A) Freshly isolated intact Soleus (SOL) muscle 
isolated from WT or A2 mice were injured in presence of FM1-43 dye. The images show time lapse images of 
fibers visualized for brightfield (pre injury, left panel), and for fluorescence emission of the FM dye pre and 
post injury (middle, right panels). Individual myofibers are marked by dotted white line, and arrows 
indicated the site of sarcolemmal injury. Scale bar = 20 µm. (B) Quantification of FM1-43 influx, following 
laser injury, into fiber isolated from WT in presence (n = 14 fibers) or absence of calcium (n = 4 fibers) and 
AnxA2 deficient (n = 22 fibers) mice. (C) Percentage of initial force as a result of repeated 10% lengthening 
contractions of WT or A2 Extensor Digitorum Longus (EDL) muscle from 1 year old animal (n = 3-4 animals 
each). (D) Percentage of initial force as a result of repeated 10% lengthening contractions of WT or A2 SOL 
muscle from 1 year old animal (n = 3 animals each). (E) Cross-section of EDL muscle section stained with 
procion orange following 10 repeated lengthening contractions in WT and A2 from 1 year old animal: 
brightfield (left panel) and procion orange (right panel). Scale bar = 50 µm. All images were acquired and 
scaled similarly and quantifications show means ± S.E.M. B: ** p ≤ 0.01 and *** p ≤ 0.001 compared to 
WT and ### p ≤ 0.001 compared to A2 by ANOVA ; C : * p ≤ 0.05 compared to WT by unpaired t-test.  
Fig. 1  
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Figure 2: AnxA2 deficient mice show progressive muscle weakness and decline in locomotor activity. A2 and 
parental WT mice at different ages (3 to 24 months old) were assessed for muscle strength and voluntary 
locomotor activity. (A) Forelimb grip strength measurement (GSM). (B) Specific force of isolated Extensor 
Digitorum Longus (EDL) muscle. (C - E) Voluntary locomotor activity assessed by open-field behavior 
measurements. All data are expressed as medians ± extreme values through whisker plot (n > 9 animals). 
* p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001 compared to WT by unpaired t-test.  
Fig. 2  
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Figure 3: Annexin A2 deficit does not increase muscle degeneration and inflammation. Gastrocnemius (GSC) 
muscle sections from A2, WT and dysferlin deficient (B6A/J) mice at different ages (3, 6 and 9 months old) 
were stained with haematoxylin & eosin (H&E) and various histological features were quantified. (A) 
Representative histological images of GSC muscle for WT, A2 and B6A/J mice. (B) H&E stained muscle 
sections were imaged from >4 independent animals and the entire muscle section was used to quantify the 
number of (B) degenerated fibers (open arrow), (C) inflammatory foci (white arrow) and (D) centrally 
nucleated fibers (black arrow). Scale bar = 100 µm. All data are expressed as mean ± S.E.M (n > 4 
animals). * p ≤ 0.05 and** p ≤ 0.01 compared to WT and # p ≤ 0.05 compared to A2 by Kruskal Wallis 
test.  
Fig. 3  
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Figure 4: Lack of AnxA2 reduces muscle inflammation in dysferlinopathic mouse. B6A/J and B6A/JA2 mice at 
6-24 months of age were assessed for (A) body mass and (B, C) muscle mass (Gastrocnemius, GSC or 
Tibialis Anterior, TA), as well as (D) the ability of the myofiber from Extensor Digitorum Longus (EDL) or 
biceps muscle of B6A/J (n = 13 fibers) or B6A/JA2 (n = 15 fibers) mice to repair from laser injury ex vivo. 
(E) Representative histological images of the haematoxylin & eosin stained EDL muscle cross section from 
WT, A2, B6A/J and B6A/JA2 at 24 months old. Scale bar = 100 µm.  Number of (F) degenerating muscle 
fibers (open arrow), (G) inflammatory foci (white arrow) and (H) central nucleated fibers (black arrow) were 
quantified from entire EDL muscles of WT, A2, B6A/J and B6A/JA2 at 24 months of age (n > 3 animals). (I, 
J) mRNA expression level (normalized to HPRT and presented as fold-change over the WT) for (I) various 
inflammatory cell population and (J) genes involved in TLR-signaling response in A2, B6A/J or B6A/JA2 GSC 
muscle at 24 months (n > 3 animals). All data are expressed as means ± S.E.M. $$ p ≤ 0.01 compared to 
B6A/J by unpaired t-test. * p ≤ 0.05 and ** p ≤ 0.01 compared to WT and ## p ≤ 0.01 compared to A2 by 
Kruskal Wallis test.  
Fig. 4  
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Figure 5: Lack of AnxA2 reduces fatty replacement of dysferlinopathic muscles. Gastrocnemius muscle from 
12 month old WT, A2, B6A/J and B6A/JA2 mice were stained with (A) haematoxylin & eosin, (B) Oil Red O 
and (C) immunostained for Perilipin1 (red). Scale = 200 µm for A & B and 100 µm for C. (D) Using images 
of whole muscle section the number of perlilipin1 stained foci were quantified (n = 3 animals each). Blue: 
DAPI, Green: Wheat germ Agglutinin (Alexa Fluor 488 conjugate), and Red: Perilipin1 (Alexa fluor 568 
conjugate).The plots represent mean ± SEM. * p ≤ 0.05 compared to WT by Kruskal Wallis test.  
Fig. 5  
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Figure 6: Lack of AnxA2 improves dysferlinopathic muscle function. (A, B). Forelimb and hindlimb grip 
strength (GSM) measurement of B6A/J or B6A/JA2 mice at < 6 months and WT, B6A/J or B6A/JA2 at > 20 
months (n > 10 animals). (C) Percentage of initial force as a result of successive 10% lengthening 
contractions of B6A/J or B6A/JA2 Extensor Digitorum Longus (EDL) muscle from 6 months or 1 year old 
animal (n > 4 animals). (D) Specific force of EDL muscle from B6A/J or B6A/JA2 mice at 6, 12 and 24 
months (n > 6 animals). (E-G) Voluntary locomotor activity assessed by open-field behavioral activity 
measurements of B6A/J or B6A/JA2 mice at < 6 months and WT, B6A/J or B6A/JA2 mice at > 20 months (n 
> 10 animals). Box whisker plots show median ± extreme values, while line plot (C) shows means ± S.E.M. 
A, B, E-G : * p ≤ 0.05 and *** p ≤ 0.001 compared to WT and $ p ≤ 0.05, $$ p ≤ 0.01 and $$$ ≤ 0.001 
compared to B6A/J by Kruskal Wallis test ; C :  * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001 compared to 
B6A/J by ANOVA.  
Fig. 6  
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